Back to top
more

Travere Therapeutics (TVTX)

(Real Time Quote from BATS)

$5.24 USD

5.24
480,452

-0.21 (-3.85%)

Updated Apr 25, 2024 11:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TVTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 567 450 553 362 399
Receivables 21 17 16 33 18
Notes Receivable 0 0 0 0 0
Inventories 9 7 7 8 6
Other Current Assets 19 13 6 8 6
Total Current Assets 617 486 583 410 429
Net Property & Equipment 7 9 11 9 3
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 104 145 148 154 158
Deposits & Other Assets 42 11 11 33 15
Total Assets 789 673 777 607 605
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 42 17 15 12 27
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 119 96 75 57 52
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 25 30 24 17
Total Current Liabilities 178 142 124 93 95
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 11 20 0 0
Convertible Debt 377 376 227 215 205
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 74 72 88 83
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 588 630 475 396 384
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,328 1,060 1,069 798 637
Retained Earnings -1,126 -1,014 -766 -586 -416
Other Equity -1 -3 -1 -1 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 201 43 302 211 221
Total Liabilities & Shareholder's Equity 789 673 777 607 605
Total Common Equity 201 43 302 211 221
Shares Outstanding 75.10 64.10 61.20 51.00 42.90
Book Value Per Share 2.67 0.67 4.94 4.14 5.16

Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 567 635 491 562
Receivables NA 21 15 20 22
Notes Receivable NA 0 0 0 0
Inventories NA 9 21 19 7
Other Current Assets NA 19 16 12 15
Total Current Assets NA 617 686 542 605
Net Property & Equipment NA 7 8 9 9
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 104 107 154 163
Deposits & Other Assets NA 42 13 12 11
Total Assets NA 789 833 736 808
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 42 25 20 17
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 119 96 89 86
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 12 14 22 24
Total Current Liabilities NA 178 139 136 131
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2 5 7 9
Convertible Debt NA 377 377 376 376
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 8 76 77
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 588 553 620 619
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,328 1,319 1,307 1,292
Retained Earnings NA -1,126 -1,035 -1,186 -1,101
Other Equity NA -1 -4 -4 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 201 280 116 189
Total Liabilities & Shareholder's Equity NA 789 833 736 808
Total Common Equity 0 201 280 116 189
Shares Outstanding 76.10 75.10 75.00 74.60 74.50
Book Value Per Share 0.00 2.67 3.73 1.56 2.54